Literature DB >> 6407501

A double-blind controlled clinical trial comparing fluvoxamine with imipramine.

J D Guelfi, J F Dreyfus, P Pichot.   

Abstract

1 The effects of fluvoxamine to a maximum of 300 mg daily were compared with those of imipramine to a maximum of 200 mg daily, in 151 patients with primary major depression. 2 Four weeks of treatment with fluvoxamine resulted in 67.2% improvement (+/- s.d. 21.6) on the Hamilton Rating Scale for Depression (26 items). Treatment with imipramine showed 62.1% improvement (+/- s.d. 29.5) on this scale. 3 Fluvoxamine had no untoward effects on the cardiovascular system, while imipramine produced systematic increases in the postural fall in blood pressure. Dry mouth, nausea, daytime somnolence and tremor were seen with fluvoxamine treatment, while imipramine was associated with dry mouth, daytime somnolence, dizziness and tremor. 4 We conclude that fluvoxamine seems to have the same general antidepressant efficacy as imipramine. It was not associated with any safety problems and was generally well tolerated.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6407501      PMCID: PMC1427660          DOI: 10.1111/j.1365-2125.1983.tb02131.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  Abnormalities of indoleamines in affective disorders.

Authors:  A Coppen; A J Prange; P C Whybrow; R Noguera
Journal:  Arch Gen Psychiatry       Date:  1972-05

2.  5-Hydroxyindoleacetic acid levels in the cerebrospinal fluid of depressive patients treated with probenecid.

Authors:  H M van Praag; J Korf; J Puite
Journal:  Nature       Date:  1970-03-28       Impact factor: 49.962

3.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

4.  Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor.

Authors:  V Claassen; J E Davies; G Hertting; P Placheta
Journal:  Br J Pharmacol       Date:  1977-08       Impact factor: 8.739

5.  5-Hydroxytryptamine in the hind-brain of depressive suicides.

Authors:  D M Shaw; F E Camps; E G Eccleston
Journal:  Br J Psychiatry       Date:  1967-12       Impact factor: 9.319

6.  Fluvoxamine-a new serotonin re-uptake inhibitor: first clinical and psychometric experiences in depressed patients.

Authors:  B Saletu; M Schjerve; J Grünberger; H Schanda; O H Arnold
Journal:  J Neural Transm       Date:  1977       Impact factor: 3.575

7.  [Factorial structure of the Hamilton depression scale. I].

Authors:  J D Guelfi; J F Dreyfus; S Ruschel; C Blanchard; P Pichot
Journal:  Ann Med Psychol (Paris)       Date:  1981-02       Impact factor: 0.380

8.  Imipramine and desipramine plasma levels: relationship to dosage schedule and sampling time.

Authors:  V E Ziegler; J T Biggs; S H Rosen; D A Meyer; S H Preskorn
Journal:  J Clin Psychiatry       Date:  1978-08       Impact factor: 4.384

  8 in total
  9 in total

Review 1.  Serotonin and blood pressure regulation.

Authors:  Stephanie W Watts; Shaun F Morrison; Robert Patrick Davis; Susan M Barman
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

2.  A double-blind randomized study comparing imipramine with fluvoxamine in depressed inpatients.

Authors:  Walter W van den Broek; Tom K Birkenhäger; Paul G H Mulder; Jan A Bruijn; Peter Moleman
Journal:  Psychopharmacology (Berl)       Date:  2004-10       Impact factor: 4.530

Review 3.  Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.

Authors:  P Benfield; A Ward
Journal:  Drugs       Date:  1986-10       Impact factor: 9.546

4.  Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis.

Authors:  E Trindade; D Menon; L A Topfer; C Coloma
Journal:  CMAJ       Date:  1998-11-17       Impact factor: 8.262

5.  Effects of repeated doses of fluvoxamine, mianserin and placebo on memory and measures of sedation.

Authors:  H V Curran; P Shine; M Lader
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

6.  The psychopharmacological effects of repeated doses of fluvoxamine, mianserin and placebo in healthy human subjects.

Authors:  H V Curran; M Lader
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 7.  Fluvoxamine versus other anti-depressive agents for depression.

Authors:  Ichiro M Omori; Norio Watanabe; Atsuo Nakagawa; Andrea Cipriani; Corrado Barbui; Hugh McGuire; Rachel Churchill; Toshi A Furukawa
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

8.  Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive disorder (DSM III). A French/Swiss double-blind trial.

Authors:  T Bougerol; C Uchida; J P Gachoud; M Köhler; H Mikkelsen
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 9.  Comparative efficacy of antidepressants.

Authors:  S Kasper; J Fuger; H J Möller
Journal:  Drugs       Date:  1992       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.